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Abstract: Over 30 million people are currently living with human immunodeficiency virus (HIV) infection, and over 2 
million new infections occur per year. HIV has been found to directly affect vascular biology resulting in an increased risk 
of cardiovascular disease compared to uninfected persons. Although HIV infection can now be treated effectively with 
combination antiretroviral medications, significant toxicities such as hyperlipidemia, diabetes, and excess cardiovascular 
co-morbidity; as well as the potential for significant drug-drug interactions between HIV and cardiovascular medications, 
present new challenges for the management of persons infected with HIV. We first review basic principles of HIV patho-
genesis and treatment and then discuss relevant clinical management strategies that will be useful for cardiologists who 
might be involved in the care of HIV infected patients. 
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INTRODUCTION TO HIV INFECTION 
  HIV-1 is an enveloped RNA retrovirus. HIV is transmit-
ted by direct inoculation into the blood stream or after con-
tact and attachment through mucosal surfaces. HIV preferen-
tially infects CD4+ cells. HIV attaches to CD4 and other co-
receptors such as CCR5 and CXCR4 on the surface of a cell 
in order to infect that cell. Within the cell, viral RNA is tran-
scribed to DNA by the HIV reverse transcriptase. Viral DNA 
then migrates to the cell nucleus and integrates into the host 
cell genome utilizing the HIV integrase enzyme. The virus 
can remain latent, or using host factors, initiate viral tran-
scription and translation. The HIV protease enzyme cleaves 
the viral polyprotein to form mature viral particles, which are 
then released from the cell to infect other cells. In the ab-
sence of HIV treatment, ongoing viral replication and infec-
tion of cells leads to CD4+ cell destruction and depletion 
resulting in immune system dysfunction. Once the CD4 cell 
count has decreased to < 200/mm
3 or < 14%, HIV infection 
is known as the acquired immunodeficiency syndrome 
(AIDS). AIDS is manifested by development of opportunis-
tic infections (OIs) and HIV-associated malignancies [1].
  After infection the natural history of HIV disease can 
take several forms and is dependent on underlying host fac-
tors and virulence factors associated with different HIV 
strains. Most people usually have a non-specific viral illness 
after acute infection. For the majority of the HIV-infected 
population, a period of chronic (or clinically latent) infection 
can last years where the immune system is still able to func-
tion despite ongoing HIV replication and depletion of CD4 
cells. Most HIV infected people require HIV treatment at 
some point during infection. A small percentage of those 
infected are able to control viral replication over many years 
in the absence of treatment and are referred to by various 
names (i.e., long term nonprogressors, elite controllers). 
Some develop AIDS relatively quickly and are referred to as 
rapid progressors. In the absence of HIV treatment, most   
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HIV-infected persons with AIDS develop AIDS complica-
tions or death within 2-3 years. 
  UNAIDS and WHO estimate that approximately 33 mil-
lion people are HIV infected world-wide and 2.5 million 
became infected and 2.1 million died of AIDS in 2007 [2]. 
The major risk factor worldwide for HIV infection is hetero-
sexual contact. In the United States, approximately one mil-
lion people are infected with HIV, and 25% don’t know they 
are HIV infected. It is also estimated that about 40,000 new 
HIV infections occur in the U.S. every year. Although the 
average age of an HIV-infected person in the U.S. is ap-
proximately 30 years, the number of people living with HIV 
over the age of 50 years is increasing significantly [3]. This 
reflects the significant decline in HIV-associated mortality as 
a result of effective HIV treatment. 
ANTIRETROVIRAL THERAPY 
Six different classes of antiretroviral agents (ARV) have 
been approved by the U.S. FDA (Table 1). They include: 
nucleoside reverse transcriptase inhibitors (NRTIs), which 
block the viral RNA to DNA transcription process; non-
nucleoside reverse transcriptase inhibitors (NNRTIs), which 
inhibit the reverse transcriptase enzyme; protease inhibitors 
(PIs), which inhibit the viral protease enzyme; fusion inhibi-
tors which block the fusion of HIV with the host cell at the 
initial point of contact; entry inhibitors which block the entry 
of HIV into the host cell by blocking the cell-surface co-
receptor CCR5; and integrase inhibitors which prevent the 
integration of the viral DNA into the host genome. 
  Several national and international expert panels have 
established numerous HIV treatment guidelines. Recom-
mended regimens usually include three different ARV agents 
in combination, usually from two classes such as 1 NNRTI + 
2 NRTIs or 1 PI + 2 NRTIs [4]. Alternate regimens are also 
provided in the guidelines for select cases where certain 
ARV drug classes are contraindicated because of drug inter-
actions, ARV resistance, or severe intolerability to preferred 
regimens. Ritonavir deserves special mention. Because it can 
inhibit certain liver cytochrome enzymes and therefore the 
metabolism of certain PIs, it is now used almost exclusively 
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tioning as a boosting agent. A decision to start treatment is 
based primarily on the CD4 count level and HIV viral load, 
and secondarily on the readiness of the patient to accept and 
adhere to life long treatment. In general, treatment is recom-
mended for those patients with a CD4 count < 350/mm
3.
HIV treatment can fail due to the acquisition of resistant vi-
rus by transmission from an exogenous source, or develop-
ment of ARV resistant virus due to poor adherence or sub-
therapeutic ARV levels secondary to drug-drug interactions. 
Although multiple ARVs are available for second line regi-
mens, multidrug resistance can be difficult to treat. The goal 
of HIV treatment is always to achieve an undetectable HIV 
viral load (< 50 copies/mL). However, in some patients this 
may no longer be possible due to acquired ARV drug resis-
tance after several failed regimens. There are no formal 
guidelines on what specific ARVs are to be used in such 
situations. Interpretation of genotypic or phenotypic resis-
tance tests and prior ARV history require an experienced 
HIV expert for optimal management. 
ANTIRETROVIRAL MEDICATION SIDE EFFECTS 
  ARVs in general have become easier for patients to toler-
ate, but a number of symptomatic side effects are still expe-
rienced. The most frequent of these is gastrointestinal intol-
erance, including nausea, vomiting, and diarrhea. These 
symptoms are commonly seen with lopinavir/ritonavir, rito-
navir in combination with any PI, tenofovir, zidovudine, 
Table 1.  Antiretroviral Agents for Treatment of HIV Infection 
Drug Class  Available Agents 
generic (common abbreviation) – alphabetic order 
Nucleoside reverse transcriptase 
inhibitor 
(NRTI) 
Abacavir (ABC) 
Didanosine (ddI) 
Emtricitabine (FTC) 
Lamivudine (3TC) 
Stavudine (d4T) 
Tenofovir (TDF) 
Zidovudine (AZT or ZDV) 
Non-nucleoside reverse transcripta-
se inhibitor 
(NNRTI) 
Delavirdine (DLV) 
Efavirenz (EFV) 
Nevirapine (NVP) 
Etravirine (ETV) 
Protease inhibitor 
(PI) 
Atazanavir (ATV) 
Darunavir (DRV) 
Fosamprenavir (fAPV) 
Indinavir (IDV) 
Nelfinavir (NFV) 
Ritonavir (RTV) 
Saquinavir (SQV) 
Tipranavir (TPV) 
Fusion inhibitor  Enfuvirtide (T-20) 
Entry inhibitor  Maraviroc (MAC) 
Integrase inhibitor  Raltegravir (RAL) 
Combination agents – NRTIs
Lamivudine/Zidovudine (Combivir®)  
Abacavir/Lamivudine (Epzicom®) 
Tenofovir/Emtricitabine (Truvada®) 
Abacavir/ Lamivudine/Zidovudine (Trizivir®) 
Combination agents – NNRTI + 2 NRTIs
Efavirenz/Emtricitabine/Tenofovir (Atripla®) 
Combination agents – PIs
Lopinavir/Ritonavir (LPV/r) (Kaletra®) HIV and Cardiovascular Disease  Current Cardiology Reviews, 2008, Vol. 4, No. 3    205
didanosine, abacavir and raltegravir. Efavirenz is associated 
with central nervous system effects, including vivid dreams, 
hallucinations, insomnia, and somnolence. Some of the older 
NRTIs, such as didanosine and stavudine, are associated 
with peripheral neuropathy. 
  Atazanavir is associated with asymptomatic hyperbiliru-
binemia, while nevirapine may cause fatal hepatic necrosis. 
Maraviroc, tipranavir, and darunavir can all cause hepatotox-
icity, particularly in those patients with hepatitis C virus 
(HCV) or hepatitis B virus (HBV) co-infection. Pancreatitis 
is seen most often with stavudine and didanosine. A life 
threatening lactic acidosis can be seen with any NRTI, but 
most commonly with stavudine. Stevens-Johnson syndrome 
can be caused by nevirapine, and abacavir can cause a fatal 
hypersensitivity reaction characterized by fever, rash, mal-
aise, fatigue, anorexia, and shortness of breath. Zidovudine 
may cause bone marrow suppression, and tenofovir fre-
quently causes renal dysfunction, but can cause acute renal 
failure as well. The PIs are associated with osteonecrosis, 
and a resultant increase in hip fractures has been reported 
[5]. 
  Many ARVs cause hyperlipidemia or the lipodystrophy 
syndrome, which is manifested by peripheral fat wasting 
(lipoatrophy) and visceral fat accumulation (lipohypertro-
phy) (Table 2) [6, 7]. This is a class effect of the PIs, and 
also occurs frequently with the NRTIs, in particular sta-
vudine [8]. The NRTIs are also associated with hepatic stea-
tosis related to mitochondrial toxicity (dysfunction and re-
duction of mitochondria), most commonly with stavudine 
and didanosine. Of the NRTIs, stavudine mainly causes in-
creased triglycerides (TG), but may also increase low density 
lipoprotein cholesterol (LDL-C) and total cholesterol (TC). 
Of the NNRTIs, efavirenz is more likely to cause hyperlipi-
demia than nevirapine. All of the PIs except atazanavir have 
been associated with hyperlipidemia. PIs, and in particular 
ritonavir-boosted PIs, cause elevations of LDL, TC and TGs 
and a decrease in high density lipoprotein cholesterol (HDL-
C) [9]. PIs suppress the breakdown of transcription factors 
Table 2.  Cardiovascular Associated Adverse Effects of HIV Medications 
Cardiovascular Effects 
Antiretroviral: Possibly PIs and other ARVs with unfavorable effects on lipids (e.g. EFV, d4T)  
Onset: months to years after beginning of therapy  
Presentation: premature coronary artery disease  
Prevalence: 3–6 per 1,000 patient-years  
Other risk factors for cardiovascular disease such as smoking, age, hyperlipidemia, hypertension, diabetes mellitus, family history of premature coronary 
artery disease, and personal history of coronary artery disease  
Monitoring: identify hyperlipidemia or hyperglycemia, cardiac risk factors 
Treatment: Lifestyle modifications: diet, exercise, and/or smoking cessation; switch to agents with less propensity for increasing cardiovascular risk factors,
i.e., NNRTI- or ATV-based regimen & avoid d4T use  
Hyperlipidemia
Antiretroviral: All PIs (except ATV); stavudine (d4T); Efavirenz (EFV) (to a lesser extent)  
Onset: weeks to months after beginning of therapy  
Presentation: increased LDL & total cholesterol (TC) & triglyceride (TG), decreased HDL  
Varies with different agents  
Prevalence: Increased TC & TG – 1.7–2.3x higher in patients receiving (non-ATV) PI; dependent on underlying hyperlipidemia. Risk based on ARV ther-
apy, PI: LPV/r & RTV -boosted PIs > NFV & APV > IDV > ATV; NNRTI: EFV more common than NVP; NRTI: d4T most common  
Monitoring: Fasting lipid profile at baseline, 3–6 months after starting new regimen, then annually or more frequently if indicated (in high-risk patients, or 
patients with abnormal baseline levels); Follow HIVMA/ACTG guidelines for management; Assess cardiac risk factor  
Treatment: Lifestyle modification: diet, exercise, and/or smoking cessation; Switching to agents with less propensity for causing hyperlipidemia; Pharma-
cologic Management: total cholesterol, LDL, TG 200–500mg/dL: “statins” – pravastatin or atorvastatin; TG >500mg/dL: gemfibrozil or micronized fenofi-
brate. Use non-PI, non-d4T based regimen; Use ATV-based regimen. 
Insulin Resistance/ Diabetes Mellitus  
Antiretroviral: All PIs  
Onset: weeks to months after beginning of therapy  
Presentation: Polyuria, polydipsia, polyphagia, fatigue, weakness; exacerbation of hyperglycemia in patients with underlying diabetes  
Prevalence: Up to 3%–5% of patients developed diabetes in some series  
Monitoring: Fasting blood glucose 1–3 months after starting new regimen, then at least every 3–6 months  
Treatment: Diet and exercise; use PI-sparing regimens, consider switching to an NNRTI-based regimen; Metformin; “Glitazones”; Sulfonylurea; Insulin 
Adapted from Table 18b, HHS guidelines January 29
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such as nuclear sterol regulatory element binding proteins 
(nSREBPs), which are important in lipid homeostasis [10-
12]. This leads to accumulation of nSREBP in the liver, 
causing increased cholesterol and fatty acid synthesis, and 
reduced triglyceride storage, leading to increased circulating 
lipids, and in the tissues, causing lipodystrophy and insulin 
resistance. PIs also inhibit the breakdown of apolipoprotein 
B via binding to a region homologous to HIV-1 protease, 
thereby causing excess production and circulation of triglyc-
eride-rich lipoproteins [11]. The inhibition of cytochrome 
P450, in particular by ritonavir, may also disrupt fat metabo-
lism by inhibiting the conversion of retinoic acid to cis-9-
retinoic acid, which results in reduced stimulation of the 
retinoic X receptor (RXR). This in turn prevents adipocyte 
differentiation and increases adipocyte apoptosis, leading to 
hyperlipidemia [13]. PIs may also bind to HIV-1 protease 
homologous regions on two proteins important for lipid me-
tabolism, cytoplasmic retinoic-acid binding protein type 1 
(CRABP-1) and low-density lipoprotein-receptor-related 
protein (LRP) [14]. CRABP-1 prevents binding with retinoic 
acid and RXR action just as cytochrome P450 does, resulting 
in hyperlipidemia [13]. LRP is responsible for chylomicron 
clearance in the liver, and for breakdown of triglycerides in 
the circulation. Therefore PI binding to LRP also contributes 
to hyperlipidemia [13].  
  The metabolic side effects of ARVs have been some of 
the most difficult to manage. The metabolic syndrome, com-
prised of abdominal obesity, hyperglycemia, dyslipidemia, 
and hypertension, is associated with PI therapy. The National 
Cholesterol Education Program Adult Treatment Panel 
(NCEP ATP) III definition of metabolic syndrome is at least 
3 of the following risk factors: waist circumference >88 cm 
[women] or >102 cm [men]; blood pressure >130/85 mm Hg 
or drug treatment for hypertension; triglycerides > 150 mg/ 
dL; fasting glucose >100 mg/dL; and HDL cholesterol <50 
mg/dL in women or <40 mg/dL in men [15]. The INITIO 
study followed patients on NNRTI or PI-based therapy [16]. 
Of 881 patients in the study, 234 (or 12 per 100 patients-
years) developed the metabolic syndrome according to 
NCEP-III criteria during 3 years of follow-up. For patients 
who developed the metabolic syndrome during therapy, the 
hazard ratio of developing cardiovascular disease was 2.73, 
and the hazard ratio for developing type 2 diabetes mellitus 
was 4.89. Those patients assigned to PI therapy were more 
likely to develop the metabolic syndrome on multivariate 
analysis. Another study found that the incidence of metabolic 
syndrome was 14% in HIV-infected adults, and was associ-
ated with increased levels of leptin and C-reactive protein 
(CRP), and decreased levels of adiponectin [17].  
  Type II diabetes has an incidence of 4.4 cases per 1000 
person-years of follow-up in HIV-infected patients in the 
Swiss HIV Cohort [18]. In the Data Collection on Adverse 
Events of Anti-HIV Drugs (D:A:D) study, DM incidence 
increased with cumulative exposure to ARVs, and was sig-
nificantly associated with exposure to stavudine, lamivudine, 
and didanosine [19]. In a group of minority patients in Los 
Angeles taking PIs, the incidence of diabetes was 7.2% in 3 
years of follow-up [20]. In vitro studies demonstrated that 
the PI indinavir inhibits the activity of GLUT-4, an insulin-
sensitive glucose transporter responsible for glucose uptake 
into muscle and fat cells, thereby contributing to insulin re-
sistance [21, 22]. One PI, atazanavir, did not inhibit GLUT-4 
in vitro, which helps to explain some of the clinical data 
showing less insulin resistance in patients taking atazanavir 
compared to other PIs. Healthy volunteers taking atazanavir 
have normal rates of glucose disposal, while those taking 
lopinavir/ritonavir have decreased glucose disposal [23]. 
Insulin sensitivity was unchanged in healthy volunteers tak-
ing atazanavir/ritonavir 300/100 mg once daily, but was sig-
nificantly decreased in volunteers taking lopinavir/ritonavir 
400/100 mg twice daily [24]. Increasing length of exposure 
to NRTIs is associated with insulin resistance as well. In the 
Multicenter AIDS Cohort Study, cumulative exposure to 
NRTIs was associated with fasting hyperinsulinemia while 
PIs and NNRTIs, surprisingly, were not [25]. Of all the 
ARVs, stavudine was associated with the highest risk of hy-
perinsulinemia, and in another study of healthy volunteers, 
stavudine administration for one month significantly reduced 
insulin sensitivity [26].  
DRUG INTERACTION ISSUES IN HIV MANAGE-
MENT 
  In general, NNRTIs and PIs are metabolized in the liver 
and can inhibit or induce hepatic P450 cytochrome enzymes. 
In particular, CYP3A4, 2D6, 2C9, 2B6, and 2C19, could be 
induced or inhibited by various ARVs. Ritonavir is generally 
a potent inhibitor of 3A4 and 2D6, but can induce 2C9. 
Other PIs or NNRTIs could have opposite effects. Thus, me-
tabolism of a number of non-HIV related medications can be 
affected by, or directly affect HIV medications through drug-
drug interactions leading to either significant toxicity or de-
creased efficacy of the target medications. Because of similar 
metabolic pathways several CV drugs are contraindicated or 
must be used with caution in patients receiving certain HIV 
medications (Table 3). The statins simvastatin, and to a 
lesser extent lovastatin, are metabolized via CYP3A4. Flu-
vastatin is metabolized via CYP2C9. Rosuvastatin is mini-
mallymetabolizedvia CYP2C9 and CYP2C19, and is largely 
excreted in the stool non-metabolized. Pravastatin undergoes 
glucuronidation in the liver, and is renally excreted non-
metabolized. Protease inhibitors and the NNRTI delavirdine 
inhibit CYP3A4, and therefore significantly increase levels 
of simvastatin and lovastatin [27]. NRTIs are not known to 
interact with statins. Because the NNRTIs nevirapine and 
efavirenz both induce CYP3A4, they decrease the AUC of 
statins. Fibrates do not have significant interactions with 
ARVs. Other drugs such as bepridil, flecainide, propafenone, 
quinidine, and amiodarone should not be used with certain 
ARVs because of common metabolic pathways. 
  Hepatic metabolism of other drugs such as warfarin, cal-
cium channel blockers, and phosphodiesterase type 5 (PDE5) 
inhibitors (particularly in combination with nitrates) may be 
inhibited to a lesser degree and should be used with caution. 
Potential drug interactions exist between calcium channel 
blockers, in particular amlodipine, nifedipine, and verapamil, 
with PIs and NNRTIs, where levels of calcium channel 
blockers may be significantly increased. Thus, the dose of 
the calcium channel blockers may need to be reduced [29]. 
Carvedilol interacts with both PIs and NNRTIs, and caution 
should be used when co-administering it with these drugs 
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zanavir due to the possibility of additive prolongation of the 
PR interval [29]. It is safe to use atenolol with atazanavir in 
the absence of ritonavir. No PR prolongation was found in a 
clinical study of atazanavir, but the QRS interval was in-
creased an average of 5 ms [30]. There are no specific con-
traindicated drug-drug interactions between antidiabetic 
medications and antiretrovirals, however additional monitor-
ing may be necessary due to overlapping medication tox-
icities (e.g., thiazolidinediones/PIs and liver toxicity, met-
formin/NRTIs and lactic acidosis). Providers should also 
watch for potential drug-drug interactions between thia-
zolidinediones and NNRTIs or protease inhibitors, which 
could result in increased effects of the hypoglycemic agent. 
Adjust dosages of these antidiabetic drugs as needed. Some 
PIs (ritonavir, nelfinavir) can increase glucuronidation of 
fibrates, thus decreasing their effectiveness. Therefore, car-
diologists should always look at metabolic pathways when 
prescribing new medications, particularly to those HIV in-
fected patients who are already receiving ARVs. 
Table 4.  Drug interactions Between Statins and ARVs Requiring Caution, Monitoring for Toxicity, and Possibly Dose Adjustment 
Lipid Lowering Agent
†
ARV
Atorvastatin  Pravastatin  Simvastatin or Lovastatin 
Atazanavir  Levels may increase.  Start with 10 mg.  No data.  Contraindicated. 
Fosamprenavir  AUC increased 150%.  Start with 10 mg.  No data.  Contraindicated. 
Lopinavir/r  AUC increased 5.9 fold.  Start with 10 mg. 
AUC increased 33%, no dose adjustment 
necessary. 
Contraindicated. 
Darunavir/r 
10 mg dose gives 40mg exposure. Start 
with 10 mg. 
AUC increased 81%, but up to 5 fold.  Use
lowest starting dose. 
Contraindicated. 
Nelfinavir  AUC increased 74%. Start with 10 mg.  No data.  Contraindicated. 
Saquinavir/r  Levels increased 450%.  Start with 10 mg. 
Levels decreased 50%.  Use standard dose,
adjust based on lipids. 
Contraindicated. 
Tipranavir/r  AUC increased 9 fold.  Start with 10 mg.  No data.  Contraindicated. 
Efavirenz 
AUC decreased 43%.  Start with 10 mg, 
adjust dose based on lipid responses. 
Levels decreased 40%.  Use standard dose,
adjust dose based on lipids. 
Simvastatin AUC decreased by 58%.
Adjust based on lipids. 
Etravirine 
Decreased AUC 37%. Start with 10 mg, 
adjust dose based on lipid response. 
No change for pravastatin, but increased 
fluvastatin levels may require dose ad-
justment. 
Decreased levels. 
Nevirapine  No data.  No data.  No data. 
Adapted from Table 22a. HHS guidelines, January 29, 2008 [28].  
† Standard dose rosuvastatin can be used with all ARVs. 
Table 3.  Cardiovascular Medications that should not be Used with HIV Drugs 
HIV Medication  Cardiovascular Medication 
Atazanavir  Bepridil, lovastatin, simvastatin 
Darunavir/ritonavir Lovastatin,  simvastatin 
Fosamprenavir  Bepridil, lovastatin, simvastatin 
Indinavir  Amiodarone, lovastatin, simvastatin 
Lopinavir/ritonavir  Flecainide, propafenone, lovastatin, simvastatin 
Nelfinavir Lovastatin,  simvastatin 
Ritonavir  Bepridil, flecainide, propafenone, quinidine, lovastatin, simvastatin 
Saquinavir/ritonavir Lovastatin,  simvastatin 
Tipranavir/ritonavir  Bepridil, flecanide, propafenone, quinidine, amiodarone,  lovastatin, simvastatin  
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  In addition to general metabolic alterations, individual 
patient variation as a result of polymorphic differences in a 
variety of genes associated with absorption, distribution, 
metabolism, and excretion (ADME) of medications has been 
described. For example, alterations in CYP2B6 (AA 516 T/T 
genotype) have resulted in increased efavirenz plasma con-
centrations compared to those without this genotype. The 
HLA-B5701 haplotype has been associated with abacavir 
hypersensitivity reactions. And active drug transporters such 
as P-glycoprotein (MDR1) polymorphisms, have also been 
associated with altered drug transport [31]. Finally, poly-
morphisms of ABCA1, APOA5, APOC3, APOE, and CETP 
have been associated with increased lipid levels in HIV in-
fected patients using ARVs [32].  
PATHOPHYSIOLOGY OF HIV-ASSOCIATED CAR-
DIOVASCULAR DISEASE 
Chronic inflammation, hypercoagulability and platelet 
activation all contribute to endothelial dysfunction, and are a 
probable link between HIV and cardiovascular disease. HIV 
influences endothelial function via activated monocytes and 
resultant cytokine secretion, and via a direct effect of the 
secreted HIV proteins tat and gp120. A simple measure of 
the chronic inflammation in HIV-infected patients is the 
higher levels of high sensitivity C-reactive protein (CRP) 
found in HIV-infected patients compared to control subjects, 
indicating a higher risk for cardiovascular events [33]. Other 
inflammatory markers such as interleukins are also elevated 
in HIV infection. Endothelial markers are increased as well, 
including soluble vascular cell adhesion molecule (sVCAM-
1), soluble intercellular adhesion molecule (sICAM-1), and 
von Willebrand factor (vWF) [34]. These markers indicate 
chronic endothelial activation and subsequent endothelial 
dysfunction, which may trigger inflammation and a hyperco-
agulable state. Endothelial activation also triggers platelet 
activation, which can upregulate adhesion molecules.
  Much is known about the direct effects of HIV on endo-
thelial function. For example, it is known that nitric oxide 
(NO) is a mediator of endothelial dysfunction in HIV infec-
tion. NO is produced in excess because of reduced expres-
sion of endothelial NO synthase (eNOS) and the resultant 
increased expression of an inducible NO synthase (iNOS) 
[35]. Then excess NO reacts with oxygen radicals to produce 
peroxynitrite, which then causes oxidative damage to the 
vascular endothelium, and decreased flow mediated dilation 
[36]. The HIV transactivator of viral replication (tat) protein 
has been found to significantly decrease eNOS mRNA and 
thus impair vasorelaxation in porcine coronary arteries [37]. 
The HIV surface protein gp120 (envelope glycoprotein) also 
stimulates NO production in activated macrophages, and 
directly activates endothelial cells resulting in increased ad-
hesion of leukocytes to the endothelium, causing endothelial 
damage [38, 39]. Clinical evidence of a link between NO and 
cardiovascular disease was found in a study of HIV-
associated cardiomyopathy. Levels of TNF- and iNOS were 
significantly higher in HIV-positive individuals with car-
diomyopathy on endomyocardial biopsy than in HIV-
negative cardiomyopathy patients [40]. 
    The HIV tat protein activates mononuclear cells to se-
crete cytokines IL-6, IL-8, and TNF-, which activate endo-
thelial cells and enhances leukocyte adhesion [39]. Both IL-6 
and IL-8 are increased in HIV-infected patients and in-
creased levels are correlated with HIV viral load as well as 
Von Willebrand Factor (vWF), and tissue-type plasminogen 
activator [41]. HIV tat protein further activates endothelial 
cells by increasing expression of adhesion molecules that 
enhance leukocyte adhesion to endothelium [39]. ICAM and 
VCAM are induced by tat in vascular endothelial cells in
vitro [42]. ICAM and VCAM levels are increased in HIV-
infected patients, and decrease with ARV treatment [34]. 
  Other effects of HIV infection include increases in IFN-,
which has been associated with hypertriglyceridemia [9, 43]. 
HIV has also been found to lower HDL-C and increase TG; 
and during progression to AIDS, LDL-C decreases [44]. Ad-
hesion molecules such as E-selectin and Von Willebrand 
Factor, which promote the endothelial adhesion of platelets, 
are also increased in HIV infection [39]. Platelet activation is 
increased via vWF in HIV infection, contributing to an in-
creased incidence of thromboembolic events [45]. Activated 
coagulation factors and reduced anticoagulants also are im-
portant in contributing to thromboembolic events in HIV 
infection. Activation of coagulation mechanisms may occur 
through endothelial activation and inflammation [34]. The 
HIV envelope protein gp120 has been shown in vitro to acti-
vate smooth muscle cells via the chemokine receptors 
CXCR4 and CCR5, and thus to cause them to express tissue 
factor [46]. Tissue factor, in turn, initiates the coagulation 
cascade leading to thrombosis. Coagulation abnormalities in 
HIV include decreases of protein S levels by 73%; increased 
levels of anticardiolipin antibodies and lupus anticoagulant, 
and decreased levels of antithrombin are also seen [39, 47].  
  Finally, HIV-induced apoptosis is another mechanism of 
endothelial injury. HIV Gp120-induced apoptosis has been 
implicated in lung endothelial injury contributing to pulmo-
nary hypertension, and HIV tat has been associated with en-
dothelial apoptosis in vitro [39]. Taken together, it is clear 
that HIV abnormally affects many aspects of cardiovascular 
physiology. 
  Many studies have evaluated the effect of HIV on endo-
thelial function, using endothelial function as a proxy for 
cardiovascular risk. Endothelium-dependent vasodilatation, 
as measured by flow-mediated dilation (FMD) of the bra-
chial artery, was significantly diminished in 75 HIV infected 
patients compared to HIV-uninfected controls in a multivari-
ate analysis study [35, 48]. In this study, smoking, male sex, 
and obesity were also independently linked to decreased 
FMD, which is a reminder of the association of smoking and 
obesity with endothelial dysfunction, and the importance of 
addressing these risk factors in HIV-infected patients. PI 
therapy was not an independent risk factor for endothelial 
dysfunction. In a separate study, 22 HIV-infected patients 
taking PIs did have impaired FMD compared to 15 HIV-
infected patients not taking PI therapy. The group taking PIs 
had significantly higher levels of chylomicron, VLDL, LDL, 
and HDL cholesterol levels, which likely contributed to the 
endothelial dysfunction seen [49]. A study in rats examined 
whether the NRTI zidovudine (AZT) causes endothelial dys-
function. AZT alone, and AZT plus indinavir both decreased 
vessel relaxation [50]. Therefore NRTIs and PIs may both 
play a role in the endothelial dysfunction seen in HIV-
infected patients. However, since ARVs reduce the endothe-HIV and Cardiovascular Disease  Current Cardiology Reviews, 2008, Vol. 4, No. 3    209
lial activation caused by uncontrolled HIV infection, their 
overall effect on endothelial function is still an area of active 
research and controversy [51]. 
CARDIOVASCULAR EPIDEMIOLOGY OF HIV IN-
FECTION 
  Premature coronary artery pathology has been reported 
among HIV-positive individuals. Autopsy studies first sug-
gested an association between vascular endothelial pathology 
and HIV [52]. Reporting of clinically evident coronary artery 
disease (CAD) has increased since the introduction of PIs in 
1996. HIV infected patients have higher rates of MI than 
non-HIV infected patients, 11.13 versus 6.98 per 1000 per-
son-years in a recent US study [53]. A recent Danish study 
found that HIV infected patients receiving highly active 
antiretroviral therapy (HAART) were more likely to be hos-
pitalized with ischemic heart disease than HIV-uninfected 
controls [54]. Similarly, a Kaiser Permanente study found a 
higher rate of cardiovascular events in HIV infected patients 
who were not receiving ARV therapy compared to HIV-
uninfected controls [55]. 
  Several large studies have compared rates of CAD among 
HIV-positive patients who are taking PIs compared to those 
who are not. The HIV Outpatient Study (HOPS) found in-
creased frequency of MIs after the introduction of PIs 
(p=0.0125), and a hazard ratio of 7.13 by univariate analysis 
for myocardial infarction in those who used PIs [56]. The 
hazard ratio on multivariate analysis was 6.51 but did not 
reach significance. Corroborating this finding was an Italian 
study that found patients who received PIs had an annual 
coronary event rate of 5.1/1000 while those who received 
NNRTIs had an event rate of 0.4/1000 (P<0.001)[57]. An-
other study using data from the HOPS study and other outpa-
tient clinics found event rates of 9.8/1000 and 6.5/1000 for 
patients who had and had not been exposed to PIs, respec-
tively (p=0.0008) [58]. A study of the French Hospital Data-
base found an increase in the relative risk of MI with increas-
ing length of time on PI therapy [59]. In a follow-up study 
combining data from HOPS and the Athena national cohort 
in the Netherlands, an increased risk of MI was found in 
those on PI therapy (hazard ratio 1.19, P= 0.04), but not on 
NNRTI therapy [60]. However, a reduction in a combined 
endpoint of death and atherosclerotic events of patients on 
NNRTI or PI-based therapy compared to patients not on 
therapy was found, underscoring the importance and positive 
benefits of HAART. 
  The D:A:D study also found that the incidence of MI 
increased with length of time on HAART, with an adjusted 
relative risk of 1.26 (26%) per year of exposure, though the 
absolute incidence of cardiac events was low at 3.5 per 1000 
person-years [61]. A subsequent analysis of the D:A:D study 
separating the effect of PIs versus NNRTIs found that pa-
tients taking PIs had an increased relative risk of MI of 16% 
per year, while the risk of MI for patients taking NNRTIs 
was not significantly increased [62, 63]. When adjusted for 
lipid levels, diabetes mellitus, and hypertension, the relative 
risk of MI per year was increased only 10%, suggesting that 
lipid changes accounted for some, but not all, of the risk as-
sociated with PI therapy. Another recent finding from the 
D:A:D study is that abacavir and didanosine were independ-
ent risk factors for MI. Recent use of abacavir or didanosine, 
regardless of duration of use, was associated with a 90% and 
49% increased risk of MI, respectively. Zidovudine, sta-
vudine, and lamivudine were not associated with increased 
risk of MI [64]. 
  However, it is important to remember that the increase in 
absolute risk attributable to PIs is small. It should be empha-
sized that the significance of an increased risk of CAD is 
dependent on the patient’s underlying cardiac risk factors. 
Since risk of CAD is increased by a factor of 1.16 per year of 
PI therapy, or a doubling of risk over a 5-year period, PIs 
will confer minimal increased risk to someone with a low 
starting risk of CAD [65]. The importance of addressing un-
derlying cardiac risk factors, such as tobacco use, must be 
emphasized. Some of the effects of PI therapy, such as 
dyslipidemia and insulin resistance, can be medically man-
aged to further reduce CV event risk. 
  Other studies have reported a decrease in CV risk in pa-
tients receiving ARV therapy. HAART appeared to decrease 
the risk of cardiac disease in the Strategies for Management 
of Antiretroviral Therapy (SMART) study. Patients in the 
ARV-sparing arm had an increased rate of cardiac events 
compared to those who remained on HAART [66]. The in-
creased rate of cardiac events could be related to the increase 
in inflammation caused by rising HIV viral loads in patients 
who stopped HAART. A recent study looked at this possibil-
ity, and found significantly increased levels of IL-6 (30% 
versus 5%) and D-dimer (16% versus 0%) in patients who 
discontinued HAART compared to those who continued 
HAART [67]. These increased levels of IL-6 and D-dimer 
were associated with cardiovascular events. A similar treat-
ment interruption study, the STACCATO trial, found in-
creased sVCAM, adiponectin, and IL-10 in the patients who 
had a treatment interruption versus those who stayed on 
ARV therapy [68]. Another treatment interruption study 
found that increases in viral load correlated with increases in 
sVCAM [69]. Corroborating the beneficial effects of 
HAART on cardiovascular risk, a large retrospective U.S. 
Department of Veterans Affairs (VA) study found that the 
admission rate for cardiovascular and cerebrovascular dis-
ease decreased from 1.7 to 0.9 per 100 patient-years from 
1995 to 2001, during the time that HAART with ritonavir-
boosted protease inhibitors became widely used. No associa-
tion was found between cardiovascular events and the use of 
PIs, NNRTIs, or NRTIs [70]. The mean follow-up time was 
15 months, and the mean time on PIs was 16 months, so this 
study may speak more to the short-term benefits of ARV 
treatment rather than the long term cardiovascular effects of 
HAART. Overall, these data on the incidence of CAD and 
MI in HIV-infected individuals support an initial decrease in 
cardiac risk with the use of ARV therapy, related to a reduc-
tion in inflammation and endothelial dysfunction caused by 
HIV. They do point to an increased cardiovascular risk in 
those on PI-based therapy, which increases with time spent 
on therapy. 
  HIV and HAART have also been associated with in-
creased carotid artery intima-media thickening, which is 
used as a surrogate for cardiovascular risk. Baseline intima-
media thickness (IMT) is higher in patients with HIV infec-
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71]. Increased IMT is associated with classic cardiovascular 
risk factors, such as older age, higher LDL cholesterol, 
smoking pack-years, and hypertension. ARV therapy has 
also been implicated; Jerico et al. found that ARV therapy 
was associated with subclinical atherosclerosis [72]. Along 
with PI exposure, lower CD4 count and genetic polymor-
phisms are also associated with progression of IMT [73, 74]. 
One of these genetic polymorphisms is in the monocyte 
chemoattractant protein-1 gene (MCP-1-2518G), and is as-
sociated with increased expression. MCP-1 attracts circulat-
ing monocytes to endothelial cells where they become foam 
cells which lodge in the endothelium and contribute to athe-
rosclerosis [74, 75]. Mutations of stromal derived factor-1, 
(SDF1), which is a chemokine receptor upregulating chemo-
attraction and adhesion, were shown to cause platelet activa-
tion in atheromas, migration of smooth muscle cells to the 
endothelium, increased expression of CX3CR1, and were 
associated with lower IMT increases [74]. Another study that 
found higher carotid IMT in HIV-infected subjects compared 
to controls was independently associated with cytomegalovi-
rus (CMV)-specific T-cell responses in the HIV-infected 
population [76]. Carotid IMT has also been found to be 
higher in HIV-infected children [77]. Other studies have 
found no association between HIV infection or PI therapy 
and IMT or IMT progression [78, 79]. However, the baseline 
IMT in these studies was much lower than other studies, 
suggesting a lack of sensitivity in detecting IMT changes 
[80]. It is most likely that HIV and PI therapy both increase 
IMT, but that the factors most important in determining athe-
rosclerotic disease are traditional risk factors. 
  Left ventricular dysfunction, dilated cardiomyopathy, and 
myocarditis all occur with increased frequency in AIDS pa-
tients. In a pre-HAART study, global LV hypokinesis was 
found in 14.5% of patients and was associated with lower 
CD4 counts, and congestive heart failure was diagnosed in 
about 2% of patients [81]. Causes may include a direct effect 
of HIV, other cardiotropic viruses, ARV toxicity, cytokines, 
opportunistic infections (OIs), illicit drug use, or nutritional 
deficiencies. In a pre-HAART series of myocardial biopsies 
in HIV patients, 5 of 33 stained positive for HIV while 16 of 
33 were positive for CMV using antisense riboprobes [82]. 
The incidence of cardiomyopathy is declining post-HAART 
[83]. Myocarditis has many causes in HIV-infected patients, 
though a specific diagnosis is rare. These include toxoplas-
mosis, tuberculosis, Cryptococcus neoformans, Aspergillus, 
Candida, cytomegalovirus, HSV, Mycobacterium avium in-
tracellulare, and HIV [84, 85]. In an Italian study, lympho-
cytic interstitial myocarditis was documented in 30 of 440 
(7%) of AIDS patients at autopsy [86]. Again, the incidence 
of myocarditis has also declined in the era of effective HIV 
treatment. 
  Pericardial disease is common in HIV-infected patients. 
In the Prospective Evaluation of Cardiac Involvement in 
AIDS (PRECIA) study, before the introduction of HAART, 
the incidence of pericardial effusion was 11% per year, and it 
was associated with shorter survival and lower CD4 counts 
[87]. A majority of the effusions were asymptomatic and 
idiopathic. They rarely cause tamponade [85]. Various OIs 
and malignancies have been reported to cause pericardial 
effusions, including Kaposi’s sarcoma, mycobacteria, CMV, 
prosthetic valve endocarditis, bacterial pericarditis caused by 
organisms such as Streptococcus pneumoniae [88], Nocardia 
[89, 90], lymphoma, and immune reconstitution inflamma-
tory syndrome secondary to Mycobacterium tuberculosis
(TB) [91]. In Africa, the majority of pericardial disease in 
HIV infected patients is caused by TB [84, 92, 93]. The inci-
dence of pericarditis has also been decreasing since the in-
troduction of HAART. In a retrospective study of the inci-
dence of cardiac disease comparing the era of mono or dual 
NRTI therapy versus HAART, the incidence of pericarditis 
had decreased from 13.5% to 3.4% [83]. Bundle branch 
block, atrial fibrillation, ischemia, and dilated cardiomyopa-
thy have similarly decreased. It is unknown if the incidence 
of pericardial effusion has declined in the HAART era. 
However, the direct effects of HIV and OIs on cardiovascu-
lar tissue and the associated cardiac disease have been sig-
nificantly reduced as a result of effective HIV treatment. 
  Thromboembolic disease has a high prevalence in HIV-
infected patients, including deep vein thrombosis, pulmonary 
embolism, thrombotic microangiopathy, and retinal venous 
thrombosis [39]. A retrospective review found a rate of deep 
venous thrombosis ten times that of HIV-uninfected patients 
in the general population [94]. Thromboembolic events have 
been found to occur at higher rates in patients with a CD4 
count <200/mm
3 compared to those with a CD4 >200/mm
3
[95]. Fultz at all looked a 37,535 HIV-infected veterans and 
the same number of controls, and found an increased rate of 
venous thromboembolism in the HIV-infected veterans both 
before 1996, in the pre-HAART era, and after 1996, in the 
HAART era after protease inhibitors became available for 
treatment [96]. A study by Lijfering et al. found that patients 
with CD4 <200/mm
3 had higher factor VIII and fibrinogen 
concentrations and lower protein S concentrations, perhaps 
explaining some of the difference in thrombosis rates [97]. 
Other factors underlying thromboembolic events in HIV-
infected patients are discussed in a previous section of this 
paper. 
  Pulmonary hypertension is significantly increased in HIV 
infected patients compared to the general population, with an 
incidence of around 0.5% reported in 1991 [98]. The same 
incidence (0.46%) was found in a 2008 study, thus refuting 
the hypothesis that the incidence had decreased since the 
introduction of HAART [99, 100]. Though HAART im-
proved mortality in HIV-infected patients with pulmonary 
hypertension in a prospective study of the Swiss HIV Co-
hort, the median survival was poor at 2.7 years from diagno-
sis [101]. Therefore, pulmonary hypertension portends a 
poorer prognosis in HIV-infected patients, despite HAART 
therapy [102]. 
  The rates of endocarditis are similar among HIV-infected 
patients with shared risk factors, such as injection drug use, 
and non-HIV-infected individuals. HIV per se does not seem 
to be a risk factor for endocarditis, though mortality may be 
higher for those with CD4 counts under 200/mm
3 [85, 103]. 
    Finally, cardiac neoplasms are a rare complication of 
AIDS. B cell lymphomas can be primary cardiac lymphomas 
or part of disseminated disease. Kaposi’s sarcoma can rarely 
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plasms are more common in HIV-infected than in HIV-
uninfected patients [85]. 
PRIMARY CARE AND CO-MORBID CONDITIONS 
ASSOCIATED WITH ARVS 
Because of the high rate of morbidity and mortality asso-
ciated with cardiovascular disease in HIV-infected patients, 
it is important to identify those at risk so they can be targeted 
for aggressive risk-management. Risk factors for cardiac 
disease include increased age, male sex, smoking, elevated 
LDL-C, low HDL-C, hypertension, and the presence of dia-
betes or peripheral vascular disease [104]. HIV-infected men 
have a greater number of these traditional CAD risk factors 
comparedtoHIV-uninfectedcontrols [105]. The Framingham 
Risk Score (FRS) has been validated as a way to quantify 10-
year coronary heard disease risk based upon age, sex, total 
cholesterol (TC), HDL-C, smoking status, and systolic blood 
pressure in the general population [106]. A link to the 10-
year risk calculator can be found at http://www.nhlbi.nih. 
gov/guidelines/cholesterol. When applied to the HIV-
infected population in the D:A:D study, the FRS slightly 
underestimated the number of CHD events for patients on 
ARV therapy, but in ARV-naïve patients, it overestimated 
the risk [107]. This may be for reasons including the direct 
effect of HIV on the endothelium, an effect of PI therapy 
apart from its metabolic effects (via up-regulation of CD36, 
which is a receptor on macrophages increasing cholesterol 
uptake and promoting foam cell formation and atherosclero-
sis [108]), an increased differential effect of cardiac disease 
risk factors on HIV patients, or the fact that in general, we 
are applying the Framingham study to a younger HIV in-
fected population than the one in which it was developed 
[109]. Since the FRS estimates 10-year cardiovascular risk, it 
may be too short to represent the lifetime risk of younger or 
middle-aged HIV-infected patients [110]. A new prediction 
tool developed from the D:A:D study, which also includes 
family history, the TC/HDL-C ratio, the presence of diabe-
tes, and the duration of exposure to PIs, performed better 
than the FRS in predicting CHD in this cohort [109, 111]. 
  Given the higher prevalence of subclinical atherosclerosis 
in HIV-positive individuals discussed above, carotid ultra-
sonography can be considered as a way to assess cardiovas-
cular risk in this population. Maggi et al. found that carotid 
vascular wall lesions were associated with PI therapy, and 
recommended screening ultrasonography for this group to 
guide cardiovascular risk management [112]. Another means 
of assessing cardiovascular risk is the high-sensitivity C-
reactive protein (CRP). This has been associated with tradi-
tional cardiovascular risk factors in HIV-infected patients, 
including waist-to-hip ratio, fasting glucose, NNRTI therapy, 
PI therapy, and the metabolic syndrome [113]. Elevated CRP 
is a marker of visceral fat accumulation and predicts higher 
cardiovascular mortality in HIV-infected women [114]. Re-
ingold et al. found that male patients with HIV monoinfec-
tion had an 88% higher CRP level than controls, while there 
was no difference in women [114]. However, HCV co-
infection was associated with 50% lower CRP levels. CRP 
levels were strongly correlated with visceral adipose tissue 
and subcutaneous adipose tissue. Of interest is that CRP lev-
els did not correlate with CD4 count or HIV viral load, or 
with ARV therapy, though other studies have found an asso-
ciation between CRP and ARV therapy [115]. In this study, 
by Masiá et al., CRP elevation of 0.3 mg/dL or greater oc-
curred in fully 40% of HIV-infected patients studied. CRP 
levels can help stratify cardiovascular risk in moderate-risk 
patients in the general population, and may have a role to 
play in risk stratification in HIV-infected patients as well. 
  Smoking has been identified as the most important modi-
fiable CAD risk factor in HIV-infected patients [116]. In the 
SIMONE study, a national Italian study of HIV-infected 
patients, smoking was the main contributor to coronary heart 
disease (CHD) risk in HIV-infected patients [117]. HIV-
infected patients have been found to have high rates of 
smoking in several studies, including in a combined analysis 
of the MACS study and the Women’s Interagency HIV 
Study (WIHS), which found about 35-40% of HIV-infected 
patients were smokers [105]. Among men in this study, HIV-
infected patients had higher smoking rates than in HIV-
negative controls. In the D:A:D study, more than 50% of the 
patients were former or current smokers, and they had dou-
ble the risk of MI [118]. In the SIMONE study, the smoking 
prevalence was 60% [119]. In the Swiss HIV Cohort the 
prevalence of current smokers was 47.6% in 2006 [120]. A 
discussion of smoking cessation methods is beyond the 
scope of this paper, but various programs have been found to 
be effective in the HIV-infected population [121, 122]. 
  Diabetes is also an important risk factor for CAD; like 
smoking, it has a higher prevalence in HIV-infected patients 
than in the general population. In the Multicenter AIDS Co-
hort (MACS) study, the incidence of diabetes in HIV-
infected men on HAART was more than four times that of 
HIV-seronegative men [123]. The metabolic syndrome has a 
similar prevalence of approximately 25% among HIV-
infected and HIV-uninfected controls, but a higher propor-
tion of HIV-infected patients with the metabolic syndrome 
have diabetes [124]. Lifestyle therapy is important in the 
treatment of metabolic syndrome and diabetes. The Diabetes 
Prevention Program found that patients with impaired glu-
cose tolerance who underwent a diet and exercise program 
were 41% less likely to develop the metabolic syndrome 
[125]. Though this study did not specifically study HIV-
positive patients, the results should be applied to all patients. 
Glycemic goals, according to the American Diabetes Asso-
ciation (ADA) are a HbA1C of  7% for most patients, with 
an option of tighter control to 6% for selected patients [126].  
  As well as addressing cardiac risk factors in diabetics, 
diabetics with HIV infection who are over age 40 or have 
any cardiac risk factors should all receive low-dose aspirin 
therapy in accordance with ADA recommendations. There is 
no known contraindication to ASA therapy in HIV-positive 
individuals. In a study of the management of diabetes in 
HIV-infected individuals, only 5% were receiving the rec-
ommended ASA therapy [127]. Along the same lines, ac-
cording to the American Heart Association, aspirin therapy 
should be recommended for any patient with an FRS of 10% 
or greater as primary prevention of MI and stroke, and the 
data from the D:A:D study, among others, suggests that 
HIV-infected patients have high levels of cardiac risk and 
disease, and should have the same therapeutic interventions 
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  Hypertension in HIV-infected individuals should be 
treated according to JNC 7 guidelines [129]. Updated hyper-
tension guidelines (JNC 8) are scheduled to be released in 
2009. Anyone with a blood pressure reading of >140/90 
mmHg on two readings on separate days should be treated 
for hypertension. Those with diabetes, chronic kidney dis-
ease, proteinuria, CAD equivalent, or a FRS  10% should 
be treated with a goal blood pressure of <130/80 mmHg. 
Lifestyle modifications are recommended for any HIV-
infected patient with hypertension, including weight loss if 
appropriate, sodium restriction and healthy diet, exercise, 
smoking cessation, and moderation in alcohol consumption. 
If systolic blood pressure is 160 mm Hg, or diastolic blood 
pressure is 100 mm Hg, then treatment should be started 
with 2 drugs simultaneously. Thiazide diuretics are first-line 
therapy unless there is a compelling indication for alternative 
treatment; such as beta-blockers (use with caution with ata-
zanavir) or angiotensin-converting enzyme (ACE) inhibitors 
for heart failure; beta-blockers or calcium-channel blockers 
(start with low doses of amlodipine, nifedipine, and verapa-
mil in HIV-infected patients) for ischemic heart disease; 
ACE inhibitors or angiotensin receptor blockers (ARBs) for 
chronic kidney disease and diabetes; and ARBs or ACE in-
hibitors for left ventricular hypertrophy. Hypertension man-
agement is an important component of lowering overall risk 
of cardiovascular disease including stroke and MI in HIV-
infected patients. 
  Lifestyle changes are the first line of therapy for ARV-
associated dyslipidemia and metabolic syndrome. A 6-month 
intensive lifestyle modification program was able to signifi-
cantly reduce waist circumference, systolic blood pressure, 
hemoglobin A1C, and lipodystrophy, but not serum lipid 
levels, in HIV-infected patients with the metabolic syndrome 
[130]. Dietary and exercise interventions were successful in 
lowering cholesterol levels 11% in one study [131]. Diet and 
exercise reduced TC by 18% and TGs by 25% in another 
study [132]. In a comparison of fish oil supplementation ver-
sus diet and exercise, triglyceride levels were decreased 
19.5% in the fish oil plus diet and exercise group versus only 
5.7% in the diet and exercise group [133].  
  Guidelines for the management of CHD risk factors in 
HIV-infected patients were published in 2003, and do not 
differ significantly from those for HIV-uninfected patients, 
and are based on the Adult Treatment Panel III (ATP III) 
guidelines from 2001 [9]. An update of the ATP III guide-
lines was published in 2004, and the ATP IV guidelines are 
expected to be released in 2009 [134]. According to the ATP 
III guidelines and update, a fasting lipid profile should be 
done on all patients before initiating ARVs, and 3-6 months 
after starting a new ARV regimen. It can then be done yearly 
if no lipid abnormalities are detected. If a patient has triglyc-
eride levels greater than 200 mg/dL prior to initiating ARV 
therapy, a lipid panel should be done within 1 to 2 months 
after starting ARV therapy, as TGs greater than 500 mg/dL 
put patients at increased risk of pancreatitis and require 
prompt treatment. LDL-C is the primary target for lipid-
lowering therapy, unless TGs are found to be >500 mg/dL, in 
which case therapy with a fibrate should be started preferen-
tially.  
  The lipid goals are based upon Framingham risk factors, 
and in general should be applied equally to HIV-infected and 
HIV-uninfected patients. Patients considered high risk are 
those with a CHD risk equivalent including a previous car-
diovascular event, diabetes, cerebrovascular disease or pe-
ripheral vascular disease, or, two or more cardiac risk factors 
(total cholesterol 240 mg/dL, systolic blood pressure 140
mmHg, diastolic blood pressure 90 mmHg, and smoking) 
with a 10-year calculated CHD risk of >20%. In high risk 
patients, the treatment goal is an LDL-C less than 100 
mg/dL. If the LDL-C is >100 mg/dL, lifestyle changes 
should be initiated and drug therapy considered. If the LDL-
C is already less than 100 mg/dL, drug therapy with an LDL-
C lowering drug should also be considered. However, if the 
patient is very high-risk, including those with acute coronary 
syndrome, or known cardiovascular disease combined with 
diabetes, metabolic syndrome, poorly controlled risk factors, 
or ongoing tobacco use, the LDL-C goal may be set to less 
than 70 mg/dL. If a patient is at moderately high risk, with 
2 risk factors, and a calculated risk between 10-20%, the 
LDL-C treatment goal is < 130 mg/dL, with initiation of 
drug therapy if the LDL-C is > 130 mg /dL. For moderately 
high risk patients, there is an option to set the treatment goal 
at an LDL-C < 100 mg/dL, and to use drug therapy if the 
LDL-C is between 100 and 129 mg/dL. Another metric for 
LDL-C goals for high and moderately high risk patients is to 
reduce the LDL-C by 30%, regardless of starting LDL-C 
level. For those patients with a moderate risk (FRS is <10% 
and 2+ risk factors), drug therapy should be considered at an 
LDL-C of 160 mg/dL. If the patient only has 0-1 risk factors 
then drug therapy would not be recommended until the LDL-
C level reaches 190 mg/dL [134]. No specific goal for HDL-
C has been set, though some trials have found treating pa-
tients with low HDL-C and high triglycerides reduces the 
risk of CHD. Nicotinic acid has been found to raise HDL-C 
and lower CHD risk. Another lipid target set forth for pa-
tients with TGs>200 is non-HDL-C, which is a measure of 
VLDL and LDL-C. This target is 30 mg/dL higher than the 
LDL-C goal. It takes into account remnant lipoproteins in 
patients with high TGs [134]. 
  Consideration should also be given to changing antiretro-
viral agents prior to the initiation of lipid-lowering medica-
tions. The benefits of switching ARV regimens are proven 
but appear to be modest compared to the use of lipid-
lowering agents, probably because all ARV regimens affect 
lipid metabolism to some degree. A one year study of HIV-
infected adults on HAART including a PI with mixed hyper-
lipidemia of TG >200 mg/dL and TC >250 mg/dL compared 
switching the PI to an NNRTI versus adding a statin [135]. 
Initiation of pravastatin or bezafibrate was more effective 
than switching to nevirapine or efavirenz in lowering TC, 
LDL-C, and TGs, and in raising HDL-C. The percentage of 
patients who reached normal cholesterol levels was 56% in 
the pravastatin arm, 42% in the bezafibrate arm, 24% in the 
nevirapine arm, and 12% in the efavirenz arm. Therefore 
lipid management was more effective after adding lipid-
lowering therapy than switching ARV regimens. In the 
Switch to Another Protease Inhibitor (SWAN) study, pa-
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unboosted atazanavir, or ritonavir boosted atazanavir if re-
ceiving tenofovir [136]. Switching therapy to atazanavir was 
successful in lowering TC and TG. Virologic rebound was 
lower in patients switched to an atazanavir-containing regi-
men (7% versus 16% kept on their old regimen), confirming 
that it does not put suppression of HIV viral replication in 
jeopardy to do so. In general, if a patient has sustained viral 
suppression, then switching ARV therapies to reduce lipid 
levels is safe [137]. Switching ARVs has also improved in-
sulin resistance. Switching from indinavir/ritonavir or lopi-
navir/ritonavir to atazanavir/ritonavir improved insulin resis-
tance in all 9 HIV-infected men evaluated in one study [138]. 
  For patients with elevated LDL-C or with elevated non-
HDL-C levels along with TG levels that are 200-500 mg/dL, 
therapy with a statin is recommended as first line treatment 
[9]. Fibrates are recommended if the serum TGs are >500 
mg/dL. The statins with the lowest potential for interaction 
with antiretroviral therapy are pravastatin, at a starting dose 
of 20-40 mg daily, and fluvastatin, starting at 20 mg daily. 
Low-dose atorvastatin (10 mg) is also a safe starting dose. 
Pravastatin cannot be used in combination with darunavir, 
because darunavir increases the AUC of pravastatin by 81% 
[139]. Low-dose atorvastatin (10mg daily), or rosuvastatin 
(10-40 mg daily), though both acceptable, may require closer 
monitoring because of increased drug interactions. Rosuvas-
tatin at 10 mg daily was effective in reducing total choles-
terol and triglycerides in HIV-infected patients with PI-
induced hyperlipidemia [140]. However, rosuvastatin should 
be used with caution as the AUC and Cmax are increased 2.1 
to 4.7-fold in combination with lopinavir/ritonavir in healthy 
volunteers [141]. For all patients on PIs, statins should be 
started at the lowest dose, and increased as needed according 
to the therapeutic response and toxicity monitoring. Simvas-
tatin and lovastatin are contraindicated in patients taking PIs 
because blood levels are increased significantly by PIs [27], 
and concomitant use has been associated with rhabdomyoly-
sis [142-147]. All statins are safe with the NRTIs and 
NNRTIs, though statin blood levels may be reduced with 
NNRTIs. The pharmacokinetics of raltegravir with pravas-
tatin is currently being studied, but as raltegravir does not 
undergo metabolism by the CYP450 system, drug interac-
tions should be minimal. Maraviroc is metabolized through 
the CYP3A isoform, but does not inhibit the CYP450 sys-
tem, so would not be expected to raise statin levels, but no 
data is available [148]. 
  It has been difficult to reach all cholesterol goals in HIV 
infected patients with statins alone [136, 149, 150]. If further 
drug therapy is needed, ezetimibe and fibrates are safe with 
all ARVs, with no and minimal interactions, respectively. 
Fibric acid derivatives may modestly reduce LDL-C levels in 
patients with normal TGs, but in patients with elevated TGs, 
LDL-C levels rise slightly [151]. Three fibrates, bezafibrate, 
gemfibrozil, and fenofibrate, were compared in a randomized 
trial for the management of ARV-associated hypertriglyc-
eridemia and hypercholesterolemia [152]. All drugs per-
formed similarly, with reductions of 41% in TGs and 23% in 
TC. Combination therapy with fenofibrate and pravastatin 
was also studied in HIV subjects with LDL-C >130 mg/dL 
and TG >200 mg/dL [151]. Each drug was initiated singly,  
and then the other was added when lipid level thresholds 
were not met. Of those on fenofibrate who then added 
pravastatin, 16% achieved National Cholesterol Education 
Program III (NCEP III [153]) goals of LDL-C <100 mg/dL 
and TG <200 mg/dL for patients with two or more cardiac 
risk factors, while 5% of those who initiated pravastatin first 
and then added fenofibrate did. This suggests that sequential 
therapy starting with fenofibrate and then pravastatin is pref-
erable, but few patients reached all target lipid levels with 
the combination. One retrospective study found the addition 
of statins and fibrates allowed more HIV patients taking 
ARVs to reach their cholesterol goals, but the success rates 
were also relatively low with less than 20% reaching NCEP 
II goals [150]. Caution must be used in combining fibrates 
with certain statins because of the increased risk of rhabdo-
myolysis [11, 147]. 
  Alternative lipid-lowering therapies to statins are an area 
of active study in HIV. A study of combination fish oil 3 g 
twice daily and fenofibrate 160 mg once daily for HIV pa-
tients not achieving TGs <200 mg/dL with either agent alone 
found that the combination provided improved TG-lowering 
effects over either drug alone, achieving the goal in 23% of 
patients [154]. Ezetimibe has also been studied as an addi-
tion to lipid management in HIV-infected individuals. It was 
given to patients who had an LDL>130 mg/dL despite treat-
ment with pravastatin [155]. At 6 weeks there were signifi-
cant falls in TC, LDL-C, and TGs, but these benefits dimin-
ished by week 24. HDL-C levels increased throughout the 
study. Ezetimibe monotherapy has also been studied in HIV-
infected patients [156]. Patients with an average baseline 
LDL-C of 121 mg/dL were started on ezetimibe or placebo. 
LDL-C decreased an average of 12% for patients receiving 
ezetimibe versus 3% for placebo. There were no significant 
changes in TGs or HDL-C.  
  Niacin is not a first-line choice for lipid therapy because 
of its propensity to cause insulin resistance [9]. However, it 
was tolerated when used for treatment of low HDL-C levels 
in HIV-infected subjects, and was associated with a signifi-
cant decrease in intra-abdominal fat [157]. Bile-sequestering 
resins should be avoided in HIV-infected individuals because 
they may be associated with increased triglyceride levels and 
their effect on antiretroviral absorption is unknown [9]. 
INTERVENTIONAL CARDIOLOGY IN HIV IN-
FECTED PATIENTS 
Solid organ transplantation has now become a successful 
reality in HIV infected patients. The first successful heart 
transplant in an HIV-infected individual was performed in 
2001, in a patient with AIDS and a history of multiple oppor-
tunistic infections [158]. The patient lived for 3.5 years post-
transplant. However, the cause of death was not reported 
[159]. A second heart transplant was reported in 2003 in a 
patient with normal CD4 counts and an undetectable HIV 
viral load [160, 161]. The patient had an uneventful recov-
ery. Another patient who acquired HIV from blood products 
transfused after her heart transplant has continued to do well 
with no major complications 10 years after her transplant 
[162]. A number of successful liver and kidney transplants 
have been performed in HIV-positive patients (19 and 26, 
respectively, in one review), with short-term survival rates  214 Current Cardiology Reviews, 2008, Vol. 4, No. 3 Dau and Holodniy 
comparable to non-HIV-infected recipients [163]. Though no 
statement has been made by national transplant organizations 
regarding transplant in HIV-positive patients, there is a 
growing consensus that HIV infection should not be an abso-
lute contraindication to solid organ transplantation. It has 
been suggested that HIV positive transplant candidates 
should have undetectable viral loads, normal CD4 counts, 
and no history of opportunistic infections [160]. However, 
because opportunistic infections can now be controlled with 
antimicrobials and immune reconstitution following HIV 
treatment, this is no longer felt to be an absolute contraindi-
cation, and only opportunistic infections with no reliable 
treatment, such as progressive multifocal leukoencephalopa-
thy, chronic cryptosporidiosis, and drug-resistant fungal in-
fections should be contraindications for transplant [164].
  Reports of percutaneous coronary intervention (PCI) 
have provided mixed results. An observational study of 50 
HIV+ and 50 HIV- patients undergoing PCI with the major-
ity receiving stents, and all patients treated with aspirin and 
clopidogrel at discharge, found no deaths and no difference 
in restenosis rates (14% v 16%, p = 0.78) at 321 days mean 
follow-up [165]. However, 5 of 12 HIV infected patients 
followed after stenting in another study had in-stent resteno-
sis after a mean follow-up of 16 months [166]. Of 24 HIV+ 
patients admitted with acute myocardial infarction in another 
study, 20% had reinfarction after discharge, and 43% of 
those who had PCI, ended up requiring target vessel revascu-
larization [167]. There is a report of late in-stent restenosis in 
an HIV-positive patient with a drug-eluting stent 23 months 
after placement, and lifelong aspirin and clopidogrel therapy 
have been recommended [168]. 
  A study of 27 HIV infected patients undergoing coronary 
artery bypass graft (CABG) compared to case controls found 
equal rates of major adverse cardiac events at 30 days, but 
increased need for revascularization at a mean follow-up of 
41 months (42% versus 25%, p=0.03) [169]. Another series 
of 37 patients looking at outcomes of cardiac surgery includ-
ing CABG and valvular replacement found acceptable out-
comes of freedom from class III angina or heart failure 
symptoms, MI, death, and repeat revascularization of 81% of 
patients at 3 years [170]. However, a note of caution was 
sounded in mentioning 6 needlestick injuries in these 37 sur-
geries, none of which resulted in HIV seroconversion. In 
conclusion, it appears that revascularization techniques in-
cluding PCI and CABG produce good clinical outcomes in 
HIV+ patients, though a higher need for subsequent revascu-
larization procedures has been documented. 
CONCLUSIONS 
It is likely that cardiologists will see HIV infected pa-
tients in consultation for medical or interventional manage-
ment of CV associated disorders. As the HIV population in 
western countries ages, it is also likely that the prevalence of 
CV disease in the HIV infected population will increase and 
cardiologists will have to balance HIV care with manage-
ment of other co-morbid conditions commonly associated 
with HIV such as hypertension, diabetes, and hyperlipide-
mia. Successful management requires understanding HIV 
specific issues, and coordination of care with the HIV spe-
cialist. 
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